4. CHRONICLE AM: OR DRUG DECRIMINALIZATION INITIATIVE FILED, CA POT
BANKING BILL DEAD FOR THIS YEAR, MORE... (9/10/19)
A drug decriminalization initiative could make its way to Oregon's 2020
ballot, South Dakota's Republican governor vows to veto any hemp bill
again next year, a California marijuana banking bill is dead for the
year, and more. https://stopthedrugwar.org/chronicle/2019/sep/10/chronicle_am_or_drug
5. CHRONICLE AM: OR PSILOCYBIN INITIATIVE ADVANCES, KAMALA HARRIS ROLLS
OUT CRIMINAL JUSTICE PLATFORM, MORE... (9/9/19)
An Oregon initiative to allow the therapeutic use of magic mushrooms is
set to begin signature gathering, an Arizona initiative to legalize
marijuana is going to get some minor tweaks, and more. https://stopthedrugwar.org/chronicle/2019/sep/09/chronicle_am_or_psilocybin
6. CHRONICLE AM: MS MEDMJ CAMPAIGN HANDS IN SIGNATURES, NY INMATES SUE
OVER PAIN MEDS, MORE... (9/6/19)
A broad coalition of civil rights and other groups are calling for
marijuana legalization and more, Mississippi activists hand in
signatures for a medical marijuana initiative, a possible culprit for
that spate of pulmonary illnesses linking to marijuana vaping has been
found, and more. https://stopthedrugwar.org/chronicle/2019/sep/06/chronicle_am_ms_medmj_campaign
7. CHRONICLE AM: JOHNS HOPKINS GETS PSYCHEDELIC CENTER, GUATEMALA STATE
OF SIEGE, MORE... (9/5/19)
Johns Hopkins University will open a new center on psychedelic research,
hemp cultivation in the US quadruples over last year, Guatemala declares
a state of seige after suspected drug traffickers killed three soldiers,
and more. https://stopthedrugwar.org/chronicle/2019/sep/05/chronicle_am_johns_hopkins_gets
We especially need help with non-deductible donations (https://secure.everyaction.com/67qFnux4lE6WkcuWQkrmzQ2) to our
501(c)(4) nonprofit. Because our newsletter reports on political
candidates, we cover the substantial cost of our web site server and
email list service fully with non-deductible funds. This is to protect
our tax-deductible 501(c)(3) nonprofit, which can't afford to be
implicated, rightly or wrongly, in candidate advocacy. Most of our
current funding is of the tax-deductible kind, especially the larger
grants and gifts.Can you make a non-deductible donation to sustain our newsletter through the campaign season? (https://secure.everyaction.com/67qFnux4lE6WkcuWQkrmzQ2) Visit our
candidates archive page here (https://stopthedrugwar.org/taxonomy/term/152).
Our web site supports both one-time donations and recurring ones, on
cycles including monthly, quarterly, annually, and other options.
Donations can also be sent by mail. For a non-deductible donation, make
your check payable to Drug Reform Coordination Network, and send to P.O.
Box 9853, Washington, DC 20016. Tax-deductible donation checks should be payable to DRCNet Foundation, same address.
The accelerating field of psychedelic research just got turbocharged.
Thanks to a group of private donors, one of the nation's premier
universities is moving forward with plans for what's believed to be the
first such research center in the country and the largest of its kind in
Johns Hopkins University in Baltimore will use $17 million in initial
funding to create the Center for Psychedelic and Consciousness Research,
the university announced last week (https://hub.jhu.edu/2019/09/04/hopkins-launches-psychedelic-center/).
The center will focus on the impact of psychedelics on behavior, brain
biology and function, learning and memory, and mood.
The move comes as renewed scientific interest in the therapeutic uses of psychedelics has mushroomed in recent years, led to a large degree by
Johns Hopkins researchers, who have been at the forefront of psychedelic research (https://hub.jhu.edu/tags/psychedelics/articles/) in the 21st
In 2000, Johns Hopkins researchers made a breakthrough, becoming the
first in the country to win regulatory approval to restart research on psychedelics in healthy people who had never used such drugs. That
resulted in a 2006 publication (https://www.hopkinsmedicine.org/Press_releases/2006/GriffithsPsilocybin.pdf) on the safety and long-lasting positive effects of a single dose of
psilocybin, which jumpstarted a renaissance of psychedelic research
Researchers linked to the university have published studies on
psychedelics in more than 60 peer-reviewed journals, finding therapeutic benefits for people suffering from conditions ranging from nicotine
addiction to depression and anxiety associated with terminal diseases.
Those studies helped pave the way for contemporary studies on the
treatment of depression. Other Johns Hopkins research has resulted in
safety guidelines for psychedelic research that have helped researchers
at other universities around the world win approval for studies, while
yet more research has dealt with the thorny problem of measuring how psychedelics affect mystical, emotional, and meditative experiences.
And now, get ready for much, much more. The new center will provide
support a half-dozen neuroscientists, experimental psychologists, and clinicians, as well as five post-doctoral scientists -- all with
expertise in psychedelic studies. Most of the research is going to
center on psilocybin, the psychoactive compound in magic mushrooms.
"The center's establishment reflects a new era of research in
therapeutics and the mind through studying this unique and remarkable
class of pharmacological compounds," said Roland Griffiths, the center's director and professor of behavioral biology in the Department of
Psychiatry and Behavioral Sciences and the Department of Neuroscience at
the Johns Hopkins University School of Medicine. "In addition to studies
on new therapeutics, we plan to investigate creativity and well-being in healthy volunteers that we hope will open up new ways to support human thriving.""I am thrilled about this magnificent opportunity that has
been provided by enlightened private funders," said James Potash, a
professor and director of the Department of Psychiatry and Behavioral
Sciences. "This center will allow our enormously talented faculty to
focus extensively on psychedelic research, where their passions lie and
where promising new horizons beckon."
Because there is no federal funding for such research, private funders
have been lined up to cover the first five years of the center's
operating expenses. Those funders are the Steven & Alexandra Cohen
Foundation and four philanthropists: Tim Ferriss, author and technology investor; Matt Mullenweg, co-founder of WordPress; Blake Mycoskie,
founder of the shoe and accessory brand TOMS; and investor Craig Nerenberg.
"We have to take braver and bolder steps if we want to help those
suffering from chronic illness, addiction, and mental health
challenges," said Alexandra Cohen. "By investing in the Johns Hopkins
center, we are investing in the hope that researchers will keep proving
the benefits of psychedelics -- and people will have new ways to heal."
The center's faculty will train graduate and medical students who want
to pursue careers in psychedelic science, where there have historically
been few avenues for career advancement.
"This represents the largest investment to date in psychedelic research,
as well as in training the next generation of psychedelic researchers,"
said Ferriss. "I sincerely hope this ambitious Johns Hopkins center will inspire others to think big and establish more psychedelic research
centers in the US and overseas, as there's never been a better time to
support such important work."
And a new era dawns.
bliss -- Cacao Powered... (-SF4ever at DSLExtreme dot com)
bobbie sellers - a retired nurse in San Francisco
"It is by will alone I set my mind in motion.
It is by the beans of cacao that the thoughts acquire speed,
the thighs acquire girth, the girth become a warning.
It is by theobromine alone I set my mind in motion."
--from Someone else's Dune spoof ripped to my taste.